Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage

N Engl J Med. 2024 Aug 22;391(8):773-774. doi: 10.1056/NEJMc2407378.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticoagulation Reversal* / adverse effects
  • Anticoagulation Reversal* / methods
  • Cerebral Hemorrhage* / chemically induced
  • Cerebral Hemorrhage* / drug therapy
  • Clinical Trials, Phase IV as Topic
  • Factor Xa Inhibitors* / adverse effects
  • Factor Xa* / administration & dosage
  • Factor Xa* / adverse effects
  • Humans
  • Multicenter Studies as Topic
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins* / administration & dosage
  • Recombinant Proteins* / adverse effects
  • Research Design
  • Rivaroxaban / adverse effects

Substances

  • Factor Xa
  • Factor Xa Inhibitors
  • PRT064445
  • Recombinant Proteins
  • Rivaroxaban